Peter MBA - Alx Oncology Chief Officer
| ALXO Stock | USD 1.47 0.06 4.26% |
Insider
Peter MBA is Chief Officer of Alx Oncology Holdings
| Age | 62 |
| Address | 323 Allerton Avenue, South San Francisco, CA, United States, 94080 |
| Phone | 650 466 7125 |
| Web | https://www.alxoncology.com |
Alx Oncology Management Efficiency
The company has return on total asset (ROA) of (0.4925) % which means that it has lost $0.4925 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9894) %, meaning that it created substantial loss on money invested by shareholders. Alx Oncology's management efficiency ratios could be used to measure how well Alx Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.7. In addition to that, Return On Capital Employed is likely to drop to -0.87. At this time, Alx Oncology's Total Assets are very stable compared to the past year. As of the 26th of November 2024, Non Current Assets Total is likely to grow to about 56.6 M, while Net Tangible Assets are likely to drop about 205.5 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| MSc MBA | Passage Bio | 55 | |
| HansGeorg Rammensee | Immatics NV | N/A | |
| Michael Diem | Century Therapeutics | 53 | |
| Path FRCP | Revolution Medicines | 61 | |
| Hunter MD | Aerovate Therapeutics | 58 | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| Jay MD | Eyepoint Pharmaceuticals | 65 | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| JD Esq | Black Diamond Therapeutics | 59 | |
| George Elston | Eyepoint Pharmaceuticals | 59 | |
| Scott Smith | Bioatla | 62 | |
| Jay Short | Bioatla | 66 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| Shane Williams | Century Therapeutics | N/A | |
| Michael Pine | Eyepoint Pharmaceuticals | 47 | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Samik MD | Cabaletta Bio | N/A | |
| Benjamin Dake | Aerovate Therapeutics | 48 | |
| Gene Kim | Dyne Therapeutics | 47 | |
| MBA MR | Aerovate Therapeutics | 62 | |
| Heow Tan | Biomea Fusion | 65 | |
Management Performance
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.49 |
Alx Oncology Holdings Leadership Team
Elected by the shareholders, the Alx Oncology's board of directors comprises two types of representatives: Alx Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alx. The board's role is to monitor Alx Oncology's management team and ensure that shareholders' interests are well served. Alx Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alx Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lisa Sauer, Senior Assurance | ||
| Peter MBA, Chief Officer | ||
| Christopher JD, General Counsel | ||
| Shelly CPA, Interim Officer | ||
| Corey Goodman, Independent Chairman | ||
| Shelly Pinto, Senior Officer | ||
| Caitlyn Doherty, Manager Communications | ||
| Sue Naim, Senior Operations | ||
| Michael Chang, Vice Operations | ||
| MS MD, Senior Pharmacovigilance | ||
| Sophia MD, Chief Director | ||
| Jaume Pons, President, Founder | ||
| Jeanne Jew, Chief Officer | ||
| Allison Dillon, Chief Officer | ||
| Chris JD, G Counsel | ||
| Jason Lettmann, CEO Director | ||
| Athanasios MD, Senior Development |
Alx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alx Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | (64.37 M) | ||||
| Shares Outstanding | 52.74 M | ||||
| Shares Owned By Insiders | 1.91 % | ||||
| Shares Owned By Institutions | 92.44 % | ||||
| Number Of Shares Shorted | 7.84 M | ||||
| Price To Book | 0.54 X | ||||
| Price To Sales | 5,906 X | ||||
| Gross Profit | 107 K |
Pair Trading with Alx Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with Alx Stock
| 0.76 | ME | 23Andme Holding | PairCorr |
| 0.86 | VALN | Valneva SE ADR | PairCorr |
| 0.73 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Alx Stock
| 0.72 | KZR | Kezar Life Sciences | PairCorr |
| 0.57 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.35 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.32 | NXGLW | NexGel Warrant | PairCorr |
The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.
The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.10) | Quarterly Revenue Growth (1.00) | Return On Assets (0.49) | Return On Equity (0.99) |
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.